As IR is the most specific metabolic risk and pathologic hallmark of NAFLD, the use of PPARγ agonists, insulin-sensitizing thiazolidinedione (TZD) molecules, to treat NASH patients has also been investigated [16], as IR is the most specific metabolic risk and pathologic hallmark of NAFLD. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.